Because separation anxiety is a clinical condition, it is possible to treat
it with a combination of medication and training, also known as behavior modification.
Elanco's Reconcile® for the treatment of canine separation anxiety in conjunction with a behavior modification plan is a chewable flavored tablet given once daily. It is approved by the FDA and has been evaluated at the recommended label
dose for one year.
Important Safety Information
- The most common adverse reactions recorded during clinical trials with Reconcile® were calm or lethargy, reduced appetite, vomiting, shaking, diarrhea, restlessness, excessive vocalization, aggression, and, in infrequent cases, seizures.
- Reconcile chewable tablets are contraindicated for dogs with epilepsy or a history of seizures; with drugs that lower the seizure threshold; with a monoamine oxidase inhibitor (MAOI) or within a minimum of 14 days of discontinuing therapy with an MAOI; in dogs with a known hypersensitivity to fluoxetine HCl or other SSRIs.
- A six week washout interval should be observed following discontinuation of therapy with Reconcile chewable tablets prior to the administration of any drug that may adversely interact with fluoxetine or norfluoxetine.
- For full product label, including complete safety information, click here.
